

Coronavirus Disease 2019 (COVID-19) Situation Report



Weekly Report No. 243 - Saudi Arabia

10 - 16 June, 2021

	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
Current	176,303,596	3,820,026	10,553,445	209,929
Last Week	173,674,509	3,744,408	10,353,336	206,573
In 7 days	2,629,087	75,618	200,109	3,356

Saudi Arabia

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	469,414	451,187	7,621	10,606	1,549	20,617,677
In 7 days	8,172	7,377	118	-	-	596,516
9/6/2021	1,286	982	16	10,217	1,553	92,227
10/6/2021	1,175	1,262	18	10,112	1,559	90,559
11/6/2021	1,077	906	16	10,267	1,562	75,059
12/6/2021	1,017	1,133	19	10,132	1,575	76,549
13/6/2021	1,109	1,148	18	10,075	1,596	83,368
14/6/2021	1,269	1,014	16	10,314	1,569	87,880
15/6/2021	1,239	932	15	10,606	1,549	90,874

HIGHLIGHTS

- Regions with the highest new infections over the past 7 days: Makkah (2,619), Riyadh (1,680), Eastern (1,278), Asir (655), Jazan (512), Madinah (507), Al Qassim (303) and Najran (166).
- More than 16.2 million COVID-19 vaccine doses administered so far in around 600 vaccination centres, where nearly 14.5 million people received at least one dose of the vaccine.
- General Directorate of Passports: All foreign nationals coming to Saudi Arabia must register their coronavirus vaccination status online before their arrival in the Kingdom.
- Ministry of Interior: It has been decided to ban unvaccinated individuals (at least one dose) from entering shopping malls, attending sporting, entertainment and cultural activities, and entering various private and public establishments starting from August 1, 2021.
- This year's Hajj will be limited to 60,000 citizens and residents inside Saudi Arabia, the portal for Hajj registration was launched on June 13 at 1 pm, more than 450,000 registered during the first 24 hours.
- 27,152 violations of the precautionary measures against COVID-19 were recorded during the period 6 – 12/06/2021.
- MoH new protocol allows conducting up to 3 COVID-19 PCR tests every month.
- Tawakkalna application is now available globally and its services can be accessed in 75 countries so far.
- Tabuk Pharmaceuticals inked deal to commercialize Moderna COVID-19 vaccine in Saudi Arabia.
- WHO publishes a policy brief on young people and COVID-19: Behavioural considerations for promoting safe behaviours, see link.
- WHO launches guidance on developing a national deployment and vaccination plan for COVID-19 vaccines (NDVP), see link.
- WHO launches interim guidance on critical preparedness, readiness and response actions for COVID-19, see link.
- WHO launches document on COVID-19 natural immunity, see link.
- WHO publishes interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac, see link.
- WHO publishes interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm, 7 May 2021, see link.

IMPORTANT LINKS

- **MoH COVID-19 updates:** <https://twitter.com/saudimoh>
- **WHO's COVID-19 global situation reports:** <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>
- **WHO's COVID-19 dashboard:** <https://covid19.who.int/>
- **MoH COVID-19 dashboard:** <https://covid19.my.gov.sa/ar/Pages/default.aspx>
- **Young people and COVID-19: Behavioural considerations for promoting safe behaviours:** <https://www.who.int/publications/i/item/978-92-4-002831-9>
- **Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines:** <https://www.who.int/publications/i/item/WHO-2019-nCoV-Vaccine-deployment-2021.1-eng>
- **Critical preparedness, readiness and response actions for COVID-19:** <https://www.who.int/publications/i/item/critical-preparedness-readiness-and-response-actions-for-covid-19>
- **COVID-19 natural immunity:** <https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci-Brief-Immunity-passport-2021.1>
- **Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac:** https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-Sinovac-CoronaVac-2021.1
- **Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm, 7 May 2021** https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BIBP-2021.1

IMPORTANT DEVELOPMENTS

WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations





On 1st of May, WHO validated the Sinovac-CoronaVac COVID-19 vaccine for emergency use. The vaccine is produced by the Beijing-based pharmaceutical company Sinovac.

WHO's Emergency Use Listing (EUL) is a prerequisite for COVAX Facility vaccine supply and international procurement. It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.

The EUL assesses the quality, safety and efficacy of COVID-19 vaccines, as well as risk management plans and programmatic suitability, such as cold chain requirements.

The Sinovac-CoronaVac product is an inactivated vaccine. Its easy storage requirements make it very manageable and particularly suitable for low-resource settings. On the basis of available evidence, WHO recommends the vaccine for use in adults 18 years and older, in a two-dose schedule with a spacing of two to four weeks. Vaccine efficacy results showed that the vaccine prevented symptomatic disease in 51% of those vaccinated and prevented severe COVID-19 and hospitalization in 100% of the studied population.

Few older adults (over 60 years) were enrolled in clinical trials, so efficacy could not be estimated in this age group. Nevertheless, WHO is not recommending an upper age limit for the vaccine because data collected during subsequent use in multiple countries and supportive immunogenicity data suggest the vaccine is likely to have a protective effect in older persons. There is no reason to believe that the vaccine has a different safety profile in older and younger populations. WHO recommends that countries using the vaccine in older agegroups conduct safety and effectiveness monitoring to verify the expected impact and contribute to making the recommendation more robust for all countries.



IMPORTANT CONTACTS

- The National Focal Person for COVID-19 is Dr Abdullah Asiri, Assistant Deputy for Preventive Health, MoH, email: AbdullahM.Asiri@moh.gov.sa